Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioAtla (BCAB) Return on Equity (2020 - 2025)

BioAtla's Return on Equity history spans 6 years, with the latest figure at 1.73% for Q4 2025.

  • For Q4 2025, Return on Equity rose 553.0% year-over-year to 1.73%; the TTM value through Dec 2025 reached 1.73%, up 553.0%, while the annual FY2025 figure was 5.33%, 699.0% up from the prior year.
  • Return on Equity reached 1.73% in Q4 2025 per BCAB's latest filing, down from 2.71% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 7.64% in Q2 2025 to a low of 8.72% in Q1 2025.
  • Average Return on Equity over 5 years is 0.8%, with a median of 0.66% recorded in 2022.
  • The largest YoY upside for Return on Equity was 1022bps in 2025 against a maximum downside of -674bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.44% in 2021, then plummeted by -51bps to 0.66% in 2022, then plummeted by -126bps to 1.49% in 2023, then tumbled by -154bps to 3.79% in 2024, then soared by 146bps to 1.73% in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Return on Equity are 1.73% (Q4 2025), 2.71% (Q3 2025), and 7.64% (Q2 2025).